Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Фаза 2
Завершено
NCT03671330
| Заболевание | Breast Cancer |
|---|
| Фаза | Фаза 2 |
|---|
| Спонсор | Novartis Pharmaceuticals |
|---|
| Статус | Завершено |
|---|
| Участники | 327 участн. |
|---|
| Вмешательство | Ribociclib Placebo, Ribociclib, NSAI: Letrozole or Anastrazole, Goserelin |
|---|
| Дата начала | 29.08.2018 |
|---|
| Дата завершения | 25.04.2022 |
|---|
| Публикация результатов | 8.07.2026 |
|---|
Кратко
This was a randomized, double-blind, placebo-controlled study conducted in Chinese women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer, plus an open-label, single-arm pharmacokinetic (PK) subset in postmenopausal Chinese women with HR+, HER2- advanced breast cancer.
Pre and Postmenopausal Cohorts: Progressive Free Survival (PFS) Based on Local Assessment by RECIST 1.1 Guideline
After approximately 100 progression-free survival (PFS) events had been observed in each cohort, using data collected up to the analysis cut-off date of 25-Apr-2022, an average of 43 months. · Months
| Premenopausal Cohort - Ribociclib | 27.6 Months |
|---|
| Premenopausal Cohort - Placebo | 14.7 Months |
|---|
| Postmenopausal Cohort - Ribociclib | NA Months |
|---|
| Postmenopausal Cohort - Placebo | 18.5 Months |
|---|
| Hazard Ratio (HR) | 0.672 (95% CI 0.448–1.009) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.